Koers Capstone Therapeutics Corp Other OTC
Aandelen
US14068E1091
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 61,56 mln. 57,2 mln. | Omzet 2023 | 48,35 mln. 44,93 mln. | Marktkapitalisatie | 820K 762K |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 2 mln. 1,86 mln. | Nettowinst (verlies) 2023 | -3 mln. -2,79 mln. | EV/omzet 2022 | 0,56 x |
Nettoschuld 2022 | 28,78 mln. 26,74 mln. | Nettoschuld 2023 | 20,28 mln. 18,84 mln. | EV/omzet 2023 | 0,44 x |
K/w-verhouding 2022 |
-583
x | K/w-verhouding 2023 |
-0,14
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 01-09-87 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |